SenoRx was founded in 1998 to design, develop, manufacture and market minimally invasive devices for the diagnosis and treatment of breast cancer. Since its founding, SenoRx has developed multiple, proprietary technology platforms and a unique product portfolio that address a range of diagnostic and therapeutic procedures.

Company was acquired by CR Bard Inc.